CMMB

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $101k64.2k shares TrimQ1 2026 $70k $1.57 $1.56

Insider Trades

Name	Value	Action	Price	Last Price
Mor George AdiDirector, Officer: Chief Executive Officer $10k4.9k shares BuyMay 29, 2026 $2.08 $1.56
Mor George AdiDirector, Officer: Chief Executive Officer $10k4.9k shares BuyMay 29, 2026 $2.05 $1.56

News

globenewswire.comChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 14

Trade CMMB

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

CEO: Adi Mor George
IPO Date: Feb 12, 2019

Market Data

Open: $1.53
High: $1.53
Low: $1.50
Volume: 62.1K
Avg Volume: 44.9K
52W High: $4.96
52W Low: $1.35

Valuation

Market Cap: $9.4M
Enterprise Value: $3.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$11.2M
Revenue: $0
Net Income: -$9M
Cash: $7.6M
Debt: $0

Events

EarningsAug 13

EPS est. -0.04